zh-twzhen
zh-twzhen

The medical device registration application of Bonvadis for all indications of wounds has been accepted by Health Canada.

2020

Date

Title

2020-12-16

Announcement by Oneness on Nanchou Manufacturing Site Receiving GMP Certification from TFDA on Manufacturing Active Pharmaceutical Ingredient

>
2020-11-18

Time Adjustment on Oneness Bio’s Oral Presentation Time Slot at EWMA 2020 Online Conference

>
2020-11-11

Oral presentation by Oneness Biotech at EWMA 2020 virtual conference on ON101 global Phase 3 MRCT results.

>
2020-11-05

Oneness submits an IND to TFDA on a phase II clinical trial of FB704A, a mAb developed from its own platform, for treating severe neutrophilic asthma.

>
2020-11-02

Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2020-10-30

The latest release of MSCI Taiwan Small Cap Index

>
2020-10-28

Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).

>
2020-05-26

Oneness Biotech will proceed to unblind Phase 3 data of ON101 MRCT (protocol#ON101CLCT02) according to TFDA notification letter# 1096013906

>
2020-05-14

Oneness Biotech receives upfront payment of US$14.48M from LEO Pharma A/S

>
2020-02-25

Oneness Biotech receives an upfront payment of US$4M from a global pharma company.

>
2020-02-11

Oneness Biotech, jointly with affiliate company, Microbio (Shanghai), signs a collaboration memorandum with global pharma company.

>
2020-01-03

Oneness Biotech has been invited for oral presentation at the 38th Healthcare Conference organized by J.P. Morgan

>